Cited by 356Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchAntiplatelet Therapy and Cardiovascular Diseases

The DOI matches its Crossref record, with a small difference in title or year; 9 of the 9 references it cites were found in a registry or an index.

Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes

Open access

Ray, Kausik K., Cannon, Christopher P., McCabe, Carolyn H., Cairns, Richard, Tonkin, Andrew M., Sacks, Frank M., Jackson, Graham, Braunwald, Eugene·2005·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2005.03.077

Open this paper in CoChat — free account Open PDF

Abstract

Objectives Our objective was to determine the timing of benefit with intensive statin therapy after an acute coronary syndrome (ACS) in two time windows: an early window soon after an ACS and a late window in more stable patients.Background The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) trial showed that the use of intensive statin therapy improved clinical outcomes over two years in ACS patients versus standard therapy. The relative contributions of early or late effects to the overall clinical efficacy of intensive therapy are presently unclear.Methods A total of 4,162 patients with ACS were recruited in the PROVE IT-TIMI 22 trial. Patients were randomized to intensive statin therapy (atorvastatin, 80 mg) or standard therapy (pravastatin, 40 mg). The composite triple end point of death, MI, or rehospitalization for recurrent ACS was determined in each group at 30 days. The composite triple and primary end points were assessed in stable patients from six months to the end of study, after censoring for clinical events before six months.Results The composite end point at 30 days occurred in 3.0% of patients receiving atorvastatin 80 mg versus 4.2% of patients receiving pravastatin 40 mg (hazard ratio [HR] = 0.72; 95% confidence interval [CI], 0.52 to 0.99; p = 0.046). In stable patients, atorvastatin 80 mg was associated with a composite event rate of 9.6% versus 13.1% in the pravastatin 40 mg group (HR = 0.72; 95% CI, 0.58 to 0.89; p = 0.003).Conclusions Intensive statin therapy early after ACS leads to a reduction in clinical events at 30 days, consistent with greater early pleiotropic effects. In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy. Thus, ACS patients should be started in-hospital and continued long-term on intensive statin therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2005.03.077

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citation
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Self-citation
Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban
Cannon, C. P., Weintraub, W. S., Demopoulos, L. A., Vicari, R. M., Frey, M. J., Lakkis, N. M., Neumann, F., Robertson, D. H., DeLucca, P. T., DiBattiste, P. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442501 · Cited by 2,093
Self-citation
Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease
Tuomilehto, J., Vidgrén, G., Toivanen, L., Tuomilehto‐Wolf, E., Kohtamäki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M. J., & Koskela, P. U. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,691
Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., & Ganz, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042000 · Cited by 1,325
Effect of Partial Ileal Bypass Surgery on Mortality and Morbidity from Coronary Heart Disease in Patients with Hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)
Buchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Pathological Changes in Acute Coronary Syndromes: The Role of Statin Therapy in the Modulation of Inflammation, Endothelial Function and Coagulation
Ray, K., & Cannon, C. (2004) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-004-0205-9 · Cited by 43
Self-citation

Show all 9 references

Research works printed but not linked: 1

1994, Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease, Lancet, 344, 1383

Sorted by citations

Items 201–300 of 356

Benefits of Statin Therapy in Patients With Acute Myocardial Infarction With Serum Low-Density Lipoprotein Cholesterol ≤ 50 mg/dl
Piao, Z. H., Li, J., Kim, J. H., Ahn, Y., Kim, Y., Cho, M., Kim, C. J., Kim, H.-S., Liu, B., & Jeong, M. H. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.04.003 · Cited by 9
Effect of moderate-intensity statin therapy on plaque inflammation in patients with acute coronary syndrome: A prospective interventional study evaluated by 18F-FDG PET/CT of the carotid artery
Kim, C. J., Han, E. J., Chu, E. H., Hwang, B., Kim, J.-J., Seung, K., Kim, S. H., Joon Hyun, O., & Chang, K. (2018) · Cardiology Journal · doi:10.5603/cj.a2018.0069 · Cited by 9
Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008
Lobos, J. M., Royo‐Bordonada, M. Á., Brotons, C., Álvarez-Sala, L., Armario, P., Maiques, A., Mauricio, D., Sans, S., Villar, F., Lizcano‐Álvarez, A., et al. (2009) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(09)71131-3 · Cited by 9
Impact of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome: A systematic review meta-analysis
Nagendra, L., Mahajan, K., Gupta, G., & Dutta, D. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.09.005 · Cited by 8
Why do transient ischemic attack patients have higher early stroke recurrence risk than those with ischemic stroke? Influence of patient behavior and other risk factors in the North Dublin Population Stroke Study
Akijian, L., Chróinín, D. N., Callaly, E. L., Hannon, N., Marnane, M., Merwick, Á., Sheehan, O. C., Hayden, D., Horgan, G., Duggan, J., et al. (2016) · International Journal of Stroke · doi:10.1177/1747493016669851 · Cited by 8
Antiatherosclerotic effects of statins: LDL versus non-LDL effects
Selwyn, A. P. (2007) · Current Atherosclerosis Reports · doi:10.1007/s11883-007-0034-3 · Cited by 8
Guía Europea de Prevención Cardiovascular en la Práctica Clínica: Adaptación Española del CEIPC 2008
Lobos, J. M., Royo‐Bordonada, M. Á., Brotons, C., Álvarez-Sala, L., Armario, P., Maiques, A., Mauricio, D., Sans, S., Álvarez, F. V., Lizcaino, A., et al. (2008) · doi:10.4321/repisalud.5189 · Cited by 8
Non-ST Segment Elevation Acute Coronary Syndromes: A Comprehensive Review
Martinez‐Rumayor, A., & Januzzi, J. L. (2006) · Southern Medical Journal · doi:10.1097/01.smj.0000215764.22650.29 · Cited by 8
Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome
Mensink, F. B., Los, J., ten Cate, T. J. F., Oemrawsingh, R. M., Brouwer, M. A., Messaoudi, S. E., van Royen, N., Cornel, J. H., Riksen, N. P., & van Geuns, R. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1061346 · Cited by 7
Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes
Ray, K. K., Nazer, B., Cairns, R., Gibson, C. M., & Cannon, C. P. (2010) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-010-0463-7 · Cited by 7
Self-citation
Stent Thrombosis after Coronary Stent Implantation: A Protective Effect of High-Dose Statin Therapy?
Jeger, R. V., Rocca, H. B., Bertel, O., Kiowski, W., Pfisterer, M. E., Kaiser, C. A., & for the BASKET Investigators (2013) · Cardiology · doi:10.1159/000350822 · Cited by 7
Residual Cardiovascular Risk—Is Inflammation the Primary Cause?
Schade, D. S., & Eaton, R. P. (2018) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2018.81007 · Cited by 6
Non-Cardiovascular Mortality, Low-Density Lipoprotein Cholesterol and Statins: A Meta-Regression Analysis
Razzolini, R., Tarantini, G., Ossena, G., Favaretto, E., Bilato, C., Manzato, E., Dalla‐Volta, S., & Iliceto, S. (2007) · Cardiology · doi:10.1159/000105551 · Cited by 6
Control del colesterol LDL en pacientes de muy alto riesgo vascular. Algoritmo simplificado para alcanzar objetivos de colesterol LDL «en dos pasos»
Guijarro, C., Marín, L. M., Galve, E., & Cordero, A. (2014) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2014.05.004 · Cited by 6
Improving Cardiovascular Protection: Focus On a Cardiovascular Polypill
Barrios, V., & Escobar, C. (2015) · Future Cardiology · doi:10.2217/fca.15.80 · Cited by 6
The Year in Non–ST-Segment Elevation Acute Coronary Syndrome
Giugliano, R. P., & Braunwald, E. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.042 · Cited by 6
Effect of high-intensity statin preloading on TIMI flow in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention
Shawky, A., Farag, N. M., Desoky, A. I. E., & Eletriby, K. A. (2020) · The Egyptian Heart Journal · doi:10.1186/s43044-020-00074-0 · Cited by 6
Intensive statin therapy in acute coronary syndromes
Liew, T. V., & Ray, K. K. (2008) · Current Atherosclerosis Reports · doi:10.1007/s11883-008-0023-1 · Cited by 6
Self-citation
The use of different evidence-based medications and 5-year survival after an acute coronary syndrome: An observational study
Wong, C., Tang, E. W., & Herbison, P. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.11.005 · Cited by 6
The current role of statins in acute coronary syndrome
Kumar, A., & Cannon, C. P. (2008) · Cited by 6
Self-citation
Initiating PCSK9 Inhibition in Hospital for ACS
Schwartz, G. G., & CHAITMAN, B. R. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.09.039 · Cited by 6
Seventeen years to change practice: will the 2025 ESC/EAS dyslipidaemia guidelines finally break the Sisyphean cycle?
Ray, K. K., & Kronenberg, F. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120636 · Cited by 5
Self-citation
Attainment of Canadian and European guidelines’ lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin
Leiter, L. A., Bays, H. E., Conard, S. E., Lin, J., Hanson, M. E., Shah, A. K., & Tershakovec, A. M. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02530.x · Cited by 5
Feasibility of Short-Term Aggressive Lipid-Lowering Therapy with the PCSK9 Antibody in Acute Coronary Syndrome
Yamashita, S., Sakamoto, A., Shoji, S., Kawaguchi, Y., Wakabayashi, Y., Matsunaga, M., Suguro, K., Matsumoto, Y., Takase, H., Onodera, T., et al. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10050204 · Cited by 5
Extremely high-risk patients with acute coronary syndrome: How “extreme” should lipid-lowering therapy be if the LDL-C target <40 mg/dl is considered?
Rallidis, L. S., Tsamoulis, D., Leventis, I., Kalogeras, P., Delakis, I., Samiotis, E., Kalantzis, C., Malkots, B., Tasoulas, D., Bouratzis, V., et al. (2023) · Kardiologia Polska · doi:10.33963/kp.a2023.0147 · Cited by 5
Safety and Efficacy of PCSK9 Inhibitors in Patients with Acute Coronary Syndrome Who Underwent Coronary Artery Bypass Grafts: A Comparative Retrospective Analysis
Nasso, G., Larosa, C., Bartolomucci, F., Brigiani, M. S., Contegiacomo, G., Demola, M. A., Vignaroli, W., Tripoli, A., Girasoli, C., Lisco, R., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030907 · Cited by 5
Tratamiento de las dislipemias en situaciones especiales
Goya, I. L., & Bueno, M. M. (2012) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(12)70042-0 · Cited by 6
Update on guidelines for management of hypercholesterolemia
Mannu, G., Zaman, M., Gupta, A., Rehman, H. U., & Myint, P. K. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.94 · Cited by 5
Lipid-Lowering Pharmacotherapy in Central and Eastern European Countries in Cardiovascular Prevention
Tomasik, T., Windak, A., Seifert, B., Kersnik, J., Kijowska, V., & Dubas‐Jakóbczyk, K. (2012) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248412471196 · Cited by 5
Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008
Lobos, J. M., Royo‐Bordonada, M. Á., Brotons, C., Álvarez-Sala, L., Armario, P., Maiques, A., Mauricio, D., Sans, S., Villar, F., Lizcano‐Álvarez, A., et al. (2009) · Medicina de Familia SEMERGEN · doi:10.1016/s1138-3593(09)70424-1 · Cited by 5
Statin Therapy in Patients Undergoing Coronary Artery Bypass Grafting for Acute Coronary Syndrome
Kuhn, E. W., Slottosch, I., Thielmann, M., Wendt, D., Kuhr, K., Jakob, H. G., Wahlers, T., Liakopoulos, O. J., & on behalf of the North-Rhine-Westphalia Study Group (2017) · The Thoracic and Cardiovascular Surgeon · doi:10.1055/s-0037-1602257 · Cited by 5
Are High-Risk Hypertensive Patients being Prescribed Concomitant Statin Therapy?
Chapman, R. H., Petrilla, A. A., Berman, L., Benner, J. S., & Tang, S. S. K. (2009) · American Journal of Cardiovascular Drugs · doi:10.2165/11312110-000000000-00000 · Cited by 5
Effect of Time to Titration to Maximum Dose of Statins on Cardiovascular Outcomes
Friend, A. S., Kamalesh, M., Schellhase, E. M., Eckert, G. J., & Evans, T. S. (2009) · American Journal of Cardiovascular Drugs · doi:10.1007/bf03256581 · Cited by 5
Pleiotropic Effects of Statins and Early Benefit in the PROVE IT–TIMI-22 Study
Poli, A., & Pujia, A. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.039 · Cited by 5
The Immediate Effects of Statins on Coronary Atherosclerosis
Min, J. K., Chandrashekhar, Y., & Narula, J. (2017) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2017.08.008 · Cited by 5
The Year in Non–ST-Segment Elevation Acute Coronary Syndromes
Giugliano, R. P., & D, E. B. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.040 · Cited by 5
Real-world management of hypercholesterolemia in patients after acute coronary syndrome in Greece
Massia, D., Giovas, P. P., Papadopoulos, N., Katsimagklis, G., Pissimisis, E., Patsilinakos, S. P., Pappa, E., Baltogiannis, G., Kouremenos, N., Dontas, C., et al. (2025) · Atherosclerosis Plus · doi:10.1016/j.athplu.2025.03.002 · Cited by 4
Statins in patients with acute ischemic stroke: when we should start therapy?
Yanishevskiy, S. N., Skiba, I. B., & Polushin, A. Y. (2021) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2021-27-1-16-28 · Cited by 4
Lipid Lowering Drugs in Acute Coronary Syndromes (ACS)
Arnold, N., & Köenig, W. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01163-6 · Cited by 4
High-dose atorvastatin reduces the risk of cardiovascular events in patients with percutaneous coronary intervention
Chang-qing, L., Jia, H., & Wang, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.19701 · Cited by 4
Statin Therapy Does Not Affect the Radiographic and Clinical Profile of Patients with TIA and Minor Stroke
Asdaghi, N., Coulter, J. I., Modi, J., Camden, M., Qazi, A., Goyal, M., Rundek, T., & Coutts, S. B. (2015) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4257 · Cited by 4
Treatment of hypercholesterolemia in patients with the metabolic syndrome: how do various statins compare?
Insull, W. (2006) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0483 · Cited by 4
Intensive statin therapy for treating acute coronary syndromes
Ray, K. K., & Cannon, C. P. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.10.1151 · Cited by 4
Self-citation
Role of Aggressive LDL Reduction in Patients With Coronary Heart Disease
Benge, C. D., Markley, B. M., & McFarland, M. S. (2011) · Southern Medical Journal · doi:10.1097/smj.0b013e31823c4242 · Cited by 4
Dyslipidemia Treatment in Patients with Acute Coronary Syndrome: Is It Time to Move to Combination Therapy?
Brie, D. M., Mornoş, C., Adam, O., Tîrziu, A., & Brie, A. D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186445 · Cited by 7
Polypharmacy with Multi-Mechanism Drugs: A Hidden Risk for Drug Interactions and Adverse Effects
Briones-Aranda, A. (2025) · Pharmaceutical science. · doi:10.5772/intechopen.1013524 · Cited by 3
Temporal Trends in the Use of High-Dose Potent Statins following Acute Coronary Syndrome in Israel
Elis, A., Pereg, D., Dicker, D., Gavrielov‐Yusim, N., Goldenberg, I., Matetzky, S., Kopel, E., & Klempfner, R. (2014) · Cardiology · doi:10.1159/000358378 · Cited by 3
Protective Role of Statins in Patients With Acute Coronary Syndrome Aged ≥75 Years With Low LDL-C Who Underwent Percutaneous Coronary Intervention
Congya, B., Zhao, Y., Ma, H., Han, H., Yang, S., Shi, D., Liu, Y., Fang, Z., Wang, Z., Ma, Q., et al. (2013) · Angiology · doi:10.1177/0003319713500379 · Cited by 3
Efecto temprano de las estatinas después de un infarto de miocardio. ¿Se debe a los efectos pleiotrópicos?
Martínez‐González, J., & Badimón, L. (2006) · Medicina Clínica · doi:10.1157/13085733 · Cited by 3
Clinical impact of statin intensity according to age in patients with acute myocardial infarction
Lee, K., Lee, M., Kim, D., Kim, J., Lim, S., Choo, E. H., Kim, C. J., Park, C. S., Kim, H.-Y., Yoo, K., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269301 · Cited by 3
Hazard ratio estimation and inference in clinical trials with many tied event times
Mehrotra, D. V., & Zhang, Y. (2018) · Statistics in Medicine · doi:10.1002/sim.7843 · Cited by 3
Rehabilitation (EACPR) Developed with the special contribution of the European Association for Cardiovascular Prevention & Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) : The Fifth
Vrints, C. J., Wood, D., Zamorano, J. L., Zannad, F. M., Karadeniz, Ş., Mezzani, A., Prescott, E., Ebrahim, S. B. J., Germanò, G., Hobbs, R. F., et al. (2013) · Cited by 3
Prompt impact of first prospective statin mega-trials on postoperative lipid management of CABG patients: a 20-year follow-up in a single hospital
Palomäki, A., Hällberg, V., Ala‐Korpela, M., Kovanen, P. T., & Malminiemi, K. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0292-6 · Cited by 3
Pharmacological Therapy in the Management of Acute Coronary Syndromes
Sampson, A. J., Paul, T. K., & Stouffer, G. A. (2015) · Atherosclerosis · doi:10.1002/9781118828533.ch40 · Cited by 3
Massachusetts Guidelines for Adult Diabetes Care
(2009) · State Library's electronic repository (State Library of Massachusetts) · Cited by 3
Early LDL-C Lowering Efficacy of High-intensity Atorvastatin and Ezetimibe Combination Compared with High-intensity Atorvastatin Alone in Acute Coronary Syndrome: The LAI EARLY ACS Study
Mehta, V., Agarwal, N., Mehra, P., Mehta, N., Yusuf, J., Dabla, P. K., Sukhija, S., Safal, S., Gupta, M., Kumar, S., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1444 · Cited by 2
The large clinical statin trials
Agewall, S. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.04.029 · Cited by 2
Europejskie wytyczne dotycza̧ce zapobiegania chorobom serca i naczyń w praktyce klinicznej na 2012 rok
Perk, J., Backer, G. D., Gohlke, H., Graham, I. M., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cífková, R., et al. (2012) · Ghent University Academic Bibliography (Ghent University) · Cited by 2
Wiek naczyń — u kogo i jak go oceniać? Czy możemy „odmłodzić” naczynia naszych pacjentów?
Tymińska, A., & Kapłon‐Cieślicka, A. (2019) · Choroby Serca i Naczyń · doi:10.5603/chsin.2019.0019 · Cited by 2
Prevalência de alta reatividade plaquetária em pacientes tratados com aspirina encaminhados para angiografia coronária
Manica, A., Sarmento‐Leite, R., Manfroi, C., Rodrigues, L. H. C., Gottschall, C. A. M., Marchini, J. F. M., & Croce, K. (2013) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2013005000002 · Cited by 2
Lipids and cardiovascular risk reduction - new targets, new challenges
Jackson, G. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00552a.x · Cited by 2
Self-citation
Stable and also unstable coronary disease - COURAGE and the importance of optimal medical therapy
Jackson, G. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01413.x · Cited by 2
Self-citation
Coping with new challenges in acute coronary syndromes
Théroux, P., & Labarthe, B. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70997-7 · Cited by 2
Clinical trials and health economics – A marriage of convenience or a marriage made in heaven?
Bakhai, A., & Greenberg, D. (2008) · Journal of Medical Economics · doi:10.3111/13696990802363015 · Cited by 2
Clinical opportunities and healthcare impact of optimal treatment in the post-ACS patient
Gargiulo, G., & Esposito, G. (2022) · Global & Regional Health Technology Assessment · doi:10.33393/grhta.2022.2391 · Cited by 1
A Marathon, Not a Sprint—AMUNDSEN and LDL-C Lowering After Myocardial Infarction
Ray, K. K., & Stevens, C. A. T. (2026) · JAMA · doi:10.1001/jama.2026.16837 · Cited by 1
Self-citation
Contemporary Management of ST-Segment Elevation Myocardial Infarction
Karunakaran, A., Sumaya, W., Gunn, J. P., Morton, A. C., & Storey, R. F. (2012) · Hospital Practice · doi:10.3810/hp.2012.02.963 · Cited by 1
Intensive Statin Therapy in Coronary Artery Disease: Is Lower Cholesterol Better and Safe?
Seshasai, S. R. K., & Ray, K. K. (2009) · Future Cardiology · doi:10.2217/14796678.5.2.129 · Cited by 1
Self-citation
Terapia hipercholesterolemii w schorzeniach układu sercowo-naczyniowego — jaki cel, jaka statyna, jaka dawka?
Wożakowska−Kapłon, B. (2014) · Via Medica Journals · Cited by 1
Lipid Lowering in Coronary Artery Disease
Ray, K. K., & Cannon, C. P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2358-8.00010-3 · Cited by 1
Self-citation
Statin therapy in patients with high and very high cardiovascular risk: an optimal approach
Sayutina, E. V., Shamuilova, M. M., Butorova, L. I., Михайловна, Т. Е., & Vertkin, A. L. (2020) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829//1728-8800-2020-2696 · Cited by 1
Management of Acute Myocardial Infarction
Jolobe, O. M. P. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-238-0_11 · Cited by 1
Hallmark Clinical Trials
KHAN, M. G. (2014) · Contemporary cardiology · doi:10.1007/978-1-61779-962-4_22 · Cited by 1
Lipid‐lowering treatment patterns in patients with new cardiovascular events – estimates from population‐based register data in Sweden
Hallberg, S., Banefelt, J., Fox, K. M., Mesterton, J., Johansson, G., Levin, L.-Å., Sobocki, P., & Gandra, S. R. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12769 · Cited by 1
Coronary artery disease and myocardial infarction
(2011) · Oxford University Press eBooks · doi:10.1093/med/9780199559688.003.0130 · Cited by 1
The experience of using acetylsalicylic acid in a comorbid patient with cad and type 2 diabetes
Gorokhovskaya, G. N., Yun, V. L., Vasyuk, Y. A., Maichuk, E. Y., & Ai, M. (2018) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-16-54-60 · Cited by 1
Trendi v sekundarni preventivi po srčnem infarktu – umestitev novosti
Veselič, M. T., & Šabović, M. (2022) · Slovenian Medical Journal · doi:10.6016/zdravvestn.3169
Lipids, Atherogenic Dyslipidemia, and Therapy
Levine, T. B., & Levine, A. B. (2012) · Wiley eBooks · doi:10.1002/9781118480045.ch13 · Cited by 1
Secondary prevention for coronary heart disease in the United Kingdom, low-density lipoprotein cholesterol goals and statin switching-an expression of concern
Ray, K. K., & Schofield, P. M. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01537.x · Cited by 1
Self-citation
Clinical Significance of Mild Lipid-Lowering by Statins for Prevention of Cardiovascular Disease in Japanese High-Risk Patients
Miyazaki, T., & Daida, H. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0188 · Cited by 1
Secondary Prevention of Coronary Artery Disease in Elderly Persons: A Treatise on a Report by the American Heart Association
Keller, K. B., & Lemberg, L. (2006) · American Journal of Critical Care · doi:10.4037/ajcc2006.15.5.514 · Cited by 1
The effect of dual inhibition of cholesterol in hyperlipidemia patients with acute myocardial infarction
Yi, M. Y., Bae, J. W., Hwang, K., Kim, D. W., & Cho, M. (2008) · The Korean Journal of Internal Medicine · Cited by 1
Acute Coronary Syndrome
Nguyen, T. N., Cheem, T. H., Agarwal, B., Shah, R., Nguyen, J., & Viet, N. L. (2007) · doi:10.1002/9780470750858.ch1 · Cited by 1
Medical Management of Patients with Renal Artery Stenosis
Dworkin, L. D., & Wilcox, C. S. (2008) · Elsevier eBooks · doi:10.1016/b978-141605484-9.50059-9 · Cited by 1
Reply
Cannon, C. P., Ray, K. K., & D, E. B. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.038 · Cited by 1
Self-citation
Human monocyte subsets in coronary artery disease and myocardial infarction
Tapp, L. D. (2014) · University of Birmingham Institutional Research Archive (University of Birmingham) · Cited by 1
Non‐ST Segment Elevation Acute Coronary Syndrome
FITCHETT, D. H. (2009) · Wiley eBooks · doi:10.1002/9781444309768.ch73
Statins and Cholesterol: How Low Can You Go?
Mikhailidis, D. P. (2008) · Springer eBooks · doi:10.1007/978-1-84628-919-4_14
Non Antithrombotic Postprocedural Pharmacotherapy: The Role of Statins, Beta‐Blockers, Angiotensin‐Converting Enzyme, or Aldosterone Inhibitors in Acute Coronary Syndromes and Elective Percutaneous Coronary Interventions
Ben‐Dor, I., Kornowski, R., & Fuchs, S. (2009) · Wiley eBooks · doi:10.1002/9781444306347.ch12
Chronic Obstructive Pulmonary Disease in Patients with Atherosclerosis
van Gestel, Y. R. B. M. (2010)
Module 15. Statins and their role in the prevention of cardiovascular disease
O’Donovan, K. (2012) · Nurse Prescribing · doi:10.12968/npre.2012.10.12.cpd1
Aggressive statin therapy for acute coronary syndromes
Liew, T. V., BChir, & Ray, K. K. (2007) · Current Cardiology Reports · doi:10.1007/bf02938378
Self-citation
Statins and perioperative myocardial infarction. Mechanisms of action
Levin, A. I., & Coetzee, A. (2007) · Southern African Journal of Anaesthesia and Analgesia · doi:10.1080/22201173.2007.10872496
Intensive lipid lowering in the cardiovascular patient: Who, how low, and for how long?
Nicholls, S. J., Kalidindi, S. R., & Nissen, S. E. (2007) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-007-0047-z
The ATHEROMA Study: Rapid Anti-inflammatory Effects of High-Dose Statin Pharmacotherapy Illuminated by Molecular MRI
Hucker, W. J., & Jaffer, F. A. (2010) · Current Cardiovascular Imaging Reports · doi:10.1007/s12410-009-9003-2
Till death us do part? Postoperative statin discontinuation
Levin, A. I. (2008) · Southern African Journal of Anaesthesia and Analgesia · doi:10.1080/22201173.2008.10872514
Controlling lipids after acute coronary syndromes: what is the best strategy?
Déry, J. (2011) · Clinical Lipidology · doi:10.2217/clp.11.15
Reziduálne kardiovaskulárne riziko — závažný problém, ktorý si bude vyžadova nové liečebné prístupy
Dukát, A. (2008)
Review Article: THE 22 PLEIOTROPIC PROPERTIES OF STATIN AND CARDIOVASCULAR DISEASES The Roles of Atorvastatin with Its PPECCAT-GOMMESAAB Effects
Tjokroprawiro, A. (2009) · Folia Medica Indonesiana
Therapeutic Class Overview HMG CoA Reductase Inhibitors
Xl, L. (2012)

Authors: Ray, K. K., Cannon, C. P., McCabe, C. H., Cairns, R., Tonkin, A. M., Sacks, F. M., Jackson, G., & Braunwald, E.
Affiliations: Brigham and Women's Hospital (US)
Monash University (AU)
Harvard University (US)
Guy's Hospital (GB)
Corresponding author: Cannon, Christopher P.
ORCID: Ray, Kausik K.
Cannon, Christopher P.
Tonkin, Andrew M.
Sacks, Frank M.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2005-10
Volume: 46
Issue: 8
Pages: 1405-1410
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2005.03.077
OpenAlex: W1484156179
Cited by: 356
References: 9
Citations by year: 2026: 10 · 2025: 13 · 2024: 5 · 2023: 12 · 2022: 13 · 2021: 4 · 2020: 15 · 2019: 11 · 2018: 17 · 2017: 15 · 2016: 14 · 2015: 11 · 2014: 18 · 2013: 20 · 2012: 24
FWCI: 26.64
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 2845 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Keywords: atorvastatin, acute coronary syndrome, high-intensity statin therapy, pravastatin, PROVE IT-TIMI 22, pleiotropy, myocardial infarction, hospital readmission, long-term clinical outcomes
MeSH terms: Atorvastatin, Acute Disease, Angina, Unstable, Double-Blind Method, Female, Heptanoic Acids, Humans, Male, Middle Aged, Myocardial Infarction, Pyrroles, Syndrome, Time Factors, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks